Posted On: 01/08/2015 7:17:24 AM
Post# of 30066
SAN FRANCISCO and GENEVA, Jan. 8, 2015 (GLOBE NEWSWIRE) -- Amarantus BioScience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics in Alzheimer's disease and therapeutic products in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that it will participate in the Eighth Annual OneMedForum on January 12 - 13, 2015, at the Marriott Marquis in San Francisco, CA.
The Company will present an overview of its investigational drug MANF (mesencephalic-astrocyte-derived neurotrophic factor) for the treatment of Retinitis Pigmentosa (RP) and Retinal Artery Occlusion (RAO) and its Phase 2b-ready small molecule drug candidate Eltoprazine for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD LID) and Adult ADHD. The Amarantus management team will also participate in a panel discussion on Brain Health and Neurological Diseases.
MANF Development Program Presentation
Date: Monday, January 12, 2015
Time: 4:00 p.m. Pacific Time / 7:00 p.m. Eastern Time
Presenter: Roman Urfer, Ph.D., Chief Development Officer at NeuroAssets
Brain Health and Neurological Diseases Panel
Date: Tuesday, January 13, 2015
Time: 3:00 - 3:45 p.m. Pacific Time / 6:00 - 6:45 p.m. Eastern Time
Participants: John Commissiong, Ph.D., Chief Scientific Officer
David Lowe, Ph.D., Member of the Amarantus Board of Directors
Eltoprazine Development Program Presentation
Date: Tuesday, January 13, 2015
Time: 4:20 p.m. Pacific Time / 7:20 p.m. Eastern Time
Presenter: Charlotte Keywood, M.D., Chief Medical Officer at Amarantus
Live audio webcasts of the two presentations may be accessed via the News and Events page of the Investor Relations section of the Amarantus corporate web site under the IR Calendar at www.amarantus.com. Webcast replays will be available approximately two hours after the presentation ends and will be archived for 30 days.
The Company will present an overview of its investigational drug MANF (mesencephalic-astrocyte-derived neurotrophic factor) for the treatment of Retinitis Pigmentosa (RP) and Retinal Artery Occlusion (RAO) and its Phase 2b-ready small molecule drug candidate Eltoprazine for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD LID) and Adult ADHD. The Amarantus management team will also participate in a panel discussion on Brain Health and Neurological Diseases.
MANF Development Program Presentation
Date: Monday, January 12, 2015
Time: 4:00 p.m. Pacific Time / 7:00 p.m. Eastern Time
Presenter: Roman Urfer, Ph.D., Chief Development Officer at NeuroAssets
Brain Health and Neurological Diseases Panel
Date: Tuesday, January 13, 2015
Time: 3:00 - 3:45 p.m. Pacific Time / 6:00 - 6:45 p.m. Eastern Time
Participants: John Commissiong, Ph.D., Chief Scientific Officer
David Lowe, Ph.D., Member of the Amarantus Board of Directors
Eltoprazine Development Program Presentation
Date: Tuesday, January 13, 2015
Time: 4:20 p.m. Pacific Time / 7:20 p.m. Eastern Time
Presenter: Charlotte Keywood, M.D., Chief Medical Officer at Amarantus
Live audio webcasts of the two presentations may be accessed via the News and Events page of the Investor Relations section of the Amarantus corporate web site under the IR Calendar at www.amarantus.com. Webcast replays will be available approximately two hours after the presentation ends and will be archived for 30 days.
(0)
(0)
